Protein / target

Prostate-specific antigen

KLK3P07288
UniProt: P07288
24
Research papers

Protein at a glance

Research activity

Emerging research

24 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Research activity

24 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.2,037 cites

Sweeney CJ · The New England journal of medicine · 2015

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.1,942 cites

Sartor O · The New England journal of medicine · 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.1,752 cites

Scher HI · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.1,272 cites

James ND · The New England journal of medicine · 2017

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.1,040 cites

Montgomery RB · Cancer research · 2008

Recent

Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.

Sweeney CJ · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

Kelly WK · Cancer discovery · 2024

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.

Dorff T · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial).

Kuo PH · Radiology · 2024

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.

Markowski MC · Nature communications · 2024

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.

Nguyen CB · Clinical cancer research : an official journal of the American Association for Cancer Research · 2024

Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.

Leung KH · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591.

Tagawa ST · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.

Shore ND · Prostate cancer and prostatic diseases · 2024

SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.

Enke JS · BMC cancer · 2024

Europe PMC papers linked directly to this protein.